Observing that the Maharashtra FDA is using a sword to kill a mosquito and “shoots first” before asking questions, the Bombay High Court on Tuesday asked the regulator to use its power judiciously, warning of imposing heavy costs as cases of its drastic actions have come to its notice.
Hearing a petition filed by Cadila Pharmaceuticals challenging the FDA’s action on select drugs, the high court directed the agency to grant the company a hearing before taking any drastic action.
Following the remarks made by a bench comprising Acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad, the FDA submitted that the regulator will revoke its orders against the petitioner, issue show-cause notices, and grant it a hearing before passing a reasoned order.
Cadila Pharmaceuticals Ltd has challenged the FDA’s decision to bar the sale and distribution of some of its medicines and seizure of stock worth Rs 2.45 crore across the state over branding similarities.
Government pleader Neha Bhide
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.